Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması

0 3

Proje Grubu: SBAG Sayfa Sayısı: 54 Proje No: 315S190 Proje Bitiş Tarihi: 15.07.2017 Metin Dili: Türkçe İndeks Tarihi: 12-03-2020

Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması

Öz:
Psödoeksfoliasyon sendromu (PES) hücre dışı matrikste lifsi materyallerin hem oküler dokularda hem de çeşitli iç organlarda birikmesi ile karakterize, yaşa bağlı gelişen sistemik bir bozukluktur. Psödoeksfoliasyon materyalinin, aköz hümor sıvısının drenajını sağlayan kanalları tıkaması sonucunda göz içi basıncının artması ile birlikte glokom ortaya çıkar; bu tip glokoma psödoeksfoliyatif glokom (PEG) adı verilir. Glokom dünyada görme kaybına yol açan en önemli sebeplerden biridir. PES’in patofizyolojisinde oksidatif stresin yer aldığı düşünülmektedir. PON1 oldukça bilinen bir antioksidan enzimdir ve PES’in patofizyolojisinde rolü olabileceği düşünülmektedir. Bu nedenle PON1 aktivitesini ve ifade edilme seviyesini etkileyen bazı tek nükleotit polimorfizmleri (SNP) ile PES ve PEG hastalıkları arasındaki ilişkinin incelenmesine karar verilmiştir. Bu SNP’ler 192Q/R, 55L/M, ve -107T/C polimorfizmleridir. Çalışma grubu 150 PES hastası, 150 PEG hastası ve 150 kontrolden oluşmaktadır. Kan örnekleri Sağlık Bilimleri Üniversites, Ankara Gülhane Eğitim ve Araştırma Hastanesi Göz Hastalıkları Servisince toplanmıştır. Genotipler PCR ve sonrasında RFLP tekniği kullanılarak belirlenmiştir. PCR’da kullanılan genomik DNA’lar ekibimiz tarafından tam kandan izole edilmiştir. Yapılan istatistiksel analizler sonucunda, PON1 192Q/R ve 55L/M polimorfizmlerinin kontroller için PES veya PEG riski bakımından fark yaratmadığı gözlenmiştir. 192Q/R polimorfizmi PES hastalarının PEG oluşturma riski açısından da ilişkisiz bulunmuş, ancak PES hastaları için, 55MM genotipine sahip olmanın, 55LM veya LL genotipine göre, PEG için 0.49 kat (OR=0.490, P=0.048) riskli, diğer bir ifade ile yaklaşık 2 kat koruyucu olduğu ortaya çıkmıştır. PON1 -107C aleli taşıyan genotipe sahip olmanın, taşımayan genotipe göre PES için 0.573 kat riskli (yani 1.74 kat daha koruyucu) (P=0.022) olduğu; öte yandan PES hastaları arasında C aleli taşıyan genotipe sahip olmanın, TT genotipine göre, PEG riskini 1.690 kat arttırdığı (P=0.030) hesaplanmıştır. Sonuç olarak, bu polimorfizmler PES ve PEG kapsamında ilk kez incelenmiş olup, bazı alellerin varlığı PES/PEG ile ilişkili bulunmuştur.
Anahtar Kelime: SNP psödoeksfoliasyon PON1 polimorfizm glokom

Konular: Göz Hastalıkları
Erişim Türü: Erişime Açık
  • Alpay, H., Ersoy, G. 1989. “Psödoeksfoliasyon sendromu (İstatistiksel bir çalışma)”, Türk Oftalmoloji Gazetesi, 19, 63-66.
  • Göksoy E, Demirkaya S, Oflaz S, Özge G, Mumcuoğlu T, Can Demirdöğen B. Analysis of the relationship between PON1 (paraoxonase1) 192Q/R (rs662) polymorphism with pseudoexfoliation syndrome and pseudoexfoliative glaucoma. Erciyes Tıp Genetik Günleri. 11-13 Mayıs 2017. Kayseri. Erciyes Medical Journal, Erciyes Medical Genetics Days 2017 Special Issue, S.69
  • Anastasopoulos, E., Coleman, A. L., Wilson, M. R., Sinsheimer, J. S., Yu, F., Katafigiotis, S., Founti, P., Salonikiou, A., Pappas, T., Koskosas, A., Katopodi, T., Lambropoulos, A., Topouzis, F. 2014. “Association of LOXL1 polymorphisms with pseudoexfoliation, glaucoma, intraocular pressure, and systemic diseases in a Greek population”, Investigative Ophthalmology and Visual Science, 55(7), 4238-43.
  • Yakar G, Koçan C, Öztepe T, Özge G, Mumcuoğlu T, Can Demirdöğen B. A study on the association between PON1 (paraoxonase 1) 55L/M (rs854560) polymorphism and pseudoexfoliation syndrome and pseudoexfoliative glaucoma. Erciyes Tıp Genetik Günleri. 11-13 Mayıs 2017. Kayseri. Erciyes Medical Journal, Erciyes Medical Genetics Days 2017 Special Issue, S.69
  • Aragon-Martin, J. A., Ritch, R., Liebmann, J., O'Brien, C., Blaaow, K., Mercieca, F., Spiteri, A., Cobb, C. J., Damji, K. F., Tarkkanen, A., Rezaie, T., Child, A. H., Sarfarazi, M. 2008. “Evaluation of LOXL1 gene polymorphisms in exfoliation syndrome and exfoliation glaucoma”, Molecular Vision, 14, 533-541.
  • Can Demirdöğen B, Yakar G, Göksoy E, Demirkaya S, Koçan C, Özge G, Mumcuoğlu T. Relationship Between Paraoxonase 1 (PON1) Promoter (-107T/C) and Coding Region Polymorphisms (192Q/R and 55L/M) and Pseudoexfoliation Syndrome. 10-14 Eylül 2017 tarihlerinde İsrail’de düzenlenecek 42. FEBS Kongresi’nde poster sunumu için kabul edildi. Kongre bittikten sonra FEBS Journal’da özet yayınlanacaktır.
  • Arıtürk, N., Oge, I., Yücel, O. E. 2005. “Exfoliation syndrome in middle east and black sea area of Turkey”, In: 5th International Glaucoma Symposium- IGS Final Program and Book of Abstracts, A 72.
  • Augusteyn, R. C., Duncan, G. 1981. "Mechanisms of Cataract Formation in the Human Lens", London: Academic Press, 71-116.
  • Aviram, M., Billecke, S., Sorenson, R. et al. 1998. "Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R.", Arterioscler Thromb Vasc Biol, 10:1617- 24.
  • Aviram, M., Rosenbalt, M. 2005. "Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences.", Curr Opin Lipidol, 16(4): 393-9.
  • Aviram, M., Rosenblat, M., Gaitini, D., Nitecki, S., Hoffman, A., Dornfeld, L., Volkova, N., Presser, D., Attias, J., Liker, H., Hayek, T. 2004. "Pomegranate juice consumption for 3 years by patients with carotid artery stenosis (CAS) reduces common carotid intima-media thickness (IMT), blood pressure and LDL oxidation.", Clin Nutr, 23: 423–433.
  • Aydin, M., Gencer, M., Cetinkaya, Y. 2006. “PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke”, IUBMB Life: 58(3):165–72.
  • Aynacioglu, A. S., Cascorbi, I., Mrozikiewicz, P. M., Nacak, M. , Tapanyigit, E. E., Roots, I. 1999. "Paraoxonase 1 mutations in a Turkish population.", Toxicol Appl Pharmacol, 157(3): 174-7.
  • Beatty, S., Koh, H., Henson, D., Boulton, M. 2000. "The role of oxidative stress in the pathogenesis of age-related macular degeneration.", Surv Ophthalmol, 45:115-34.
  • Blatter Garin, M. C., James, R. W., Dussoix, P. et al. 1997. "Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.", J Clin Invest, 99: 62-6.
  • Blatter, M. C., James, R. W., Messmer, S., Barja, F., Pometta, D. 1993. "Identification of a distinct human high- density lipoprotein subspecies defined by a lipoprotein-associated protein, K-85: identity of K-85 with paraoxonase.", Eur J Biochem, 211: 871-9.
  • Brophy, V. M., Hastings, M. D., Clendenning, J. B., Richter, R. J., Jarvik, G. P., Furlong, C. E. 2001a. "Polymorphisms in the human paraoxonase (PON1) promoter.", Pharmacogenetics, 11: 77-84.
  • Brophy, V. H., Jampsa, R. L., Clendenning, J. B., McKinstry, L. A. , Jarvik, G. P., Furlong, C. E. 2001b. "Effects of 5’ regulatory-region polymorphisms on paraoxonase gene (PON1) expression.", Am J Hum Genet, 68: 1428-36.
  • Brophy, V. H., Jarvik, G. P., Furlong, C. E. 2002. "PON1 polymorphisms.", In: Costa LG, Furlong CE Eds. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects, Norwell, MA: Kluwer Acad., p.53-77.
  • Burdon, K. P., Sharma, S., Hewitt, A. W., McMellon, A. E., Wang, J. J., Mackey, D. A., Mitchell, P., Craig, J. E. 2008. “Genetic analysis of the clusterin gene in pseudoexfoliation syndrome”, Molecular Vision, 14, 1727-36.
  • Campo, S., Sardo, M. A., Trimarchi, G., Bonaiuto, M., Fontana, L., Castaldo, M., Bonaiuto, A., Saitta, C., Bitto, A., Manduca, B., Riggio, S., Saitta, A. 2004. "Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians.", Experimental Gerontology, 39: 1089–1094.
  • Can Demirdöğen, B., Ceylan, O.M., Işıkoğlu, S., Mumcuoğlu, T., Erel, Ö. 2014. “Evaluation of oxidative stress and paraoxonase phenotypes in pseudoexfoliation syndrome and pseudoexfoliation glaucoma”. Clin. Lab. 60(1), 79-86.
  • Can Demirdöğen, B., Demirkaya, Ş., Türkanoğlu, A., Bek, S., Arınç, E., Adalı, O. 2009. "Analysis of paraoxonase 1 (PON1) genetic polymorphisms and activities as risk factors for ischemic stroke in Turkish population.", Cell Biochemistry and Function, 27(8): 558-567.
  • Can Demirdöğen, B., Türkanoğlu, A., Bek, S., Sanisoğlu, Y., Demirkaya, Ş., Vural, O., Arınç, E., Adalı, O. 2008. "Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke.", Clinical Biochemistry, 41 (1-2): 1-9.
  • Challa, P., Schmidt, S., Liu, Y., Qin, X., Vann, R. R., Gonzalez, P., Allingham, R. R., Hauser, M. A. 2008. “Analysis of LOXL1 polymorphisms in a United States population with pseudoexfoliation glaucoma”, Molecular Vision, 14, 146-149.
  • Chen, L., Jia, L., Wang, N., Tang, G., Zhang, C., Fan, S., Liu, W., Meng, H., Zeng, W.,Liu, N., Wang, H., Jia, H., 2009. “Evaluation of LOXL1 polymorphisms in exfoliation syndrome in a Chinese population”, Molecular Vision, 15, 2349-57.
  • Chowdhury, U. R., Madden, B. J., Charlesworth, M. C., Fautsch, M. P. 2010. “Proteome Analysis of Human Aqueous Humor”, Investigative Ophthalmology and Visual Science, 51(10), 4921-31.
  • Citirik, M., Acaroglu, G., Batman, C., Yildiran, L., Zilelioglu, O. 2007. "A possible link between the pseudoexfoliation syndrome and coronary artery disease.", Eye, 21:11-5.
  • Clendenning, J. B., Humbert, R., Green, E. D., Wood, C., Traver, D., Furlong, C. E. 1996. "Structural organization of the human PON1 gene.", Genomics, 35: 586-589.
  • Çumurcu, T., Kılıç, R., Yoloğlu, S. 2010. “The frequency of pseudoexfoliation syndrome in the middle Black Sea region of Turkey”, European Journal of Ophthalmology, 20, 1007-1011.
  • Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J., Furlong, C. E. 1996. "The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin.", Nature Genet, 14: 334–336.
  • de Champlain, J., Wu, R., Girouard, H. et al. 2004. "Oxidative stress in hypertension.", Clin Exp Hypertens, 26(7- 8):593-601.
  • Deakin, S. P., James, R. W. 2004. "Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1.", Clin Sci, 107: 435-447.
  • Debord, J., Dantoine, T., Bollinger, J. C., Abraham, M. H., Verneuil, B., Merle, L. 1998. "Inhibition of arylesterase by aliphatic alcohols.", Chem Biol Interact, 113: 105–15.
  • Draganov, D. I., La Du, B. N. 2004. "Pharmacogenetics of paraoxonases: a brief review.", Naunyn Schmiedebergs Arch Pharmacol, 369(1): 78-88.
  • Dursun, F., Ozec, A. V., Aydin, H., Topalkara, A., Dursun, A., Toker, M. I., Erdogan, H., Arici, M. K. 2015. "Total oxidative stress, paraoxonase and arylesterase levels at patients with pseudoexfoliation syndrome and pseudoexfoliative glaucoma.", Int J Ophthalmol, 8(5):985-990.
  • Eckerson, H. W., Romson, J., Wyte, C., La Du, B. N. 1983b. "The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts.", Am J Hum Genet, 35:214-27.
  • Eckerson, H. W., White, C. M., La Du, B. N. 1983a. "The human serum paraoxonase/arylesterase polymorphism.", Am J Hum Genet, 35: 1126-38.
  • Forsius, H. 1988. “Exfoliation syndrome in various ethnic populations”, Acta Ophthalmologica, 184, 71–85. Fortunato, G., Rubba, P., Panico, S. 2003. “A paraoxonase gene polymorphism, PON 1 (55) as an independent risk factor for increased carotid intima-media thickness in middle-aged women”, Atherosclerosis, 167(1): 141–148.
  • Furlong, C. E., Richter, R. J., Seidel, S. L., Motulsky, A. G. 1988. "Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon.", Am J Hum Genet, 43: 230–238.
  • Gan, K. N., Smolen, A., Eckerson, H., La Du, B.N. 1991. "Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities", Drug Metab Dispos, 19: 100-6.
  • Gartaganis, S. P., Georgakopoulos, C. D., Mela, E. K., Exarchou, A., Ziouti, N., Assouti, M., Vynios, D. H. 2002. “Matrix metalloproteinases and their inhibitors in exfoliation syndrome”, Ophthalmic Research, 34, 165-171.
  • Gartaganis, S. P., Patsoukis, N. E., Nikolopoulos, D. K., Georgiou, C. D. 2007. “Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndrome”, Eye (London, England), 21, 1406-1411.
  • Giangiacomo, A., Coleman, A. L. 2009. “The epidemiology of glaucoma”, Essentials in Ophthalmology, p13-21.
  • Harel, M., Aharoni, A., Gaidukov, L., Brumshtein, B., Khersonsky, O., Meged, R., Dvir, H., Ravelli, R. B., McCarthy, A., Toker, L., Silman, I., Sussman, J. L., Tawfik, D. S. 2004. "Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes.", Nat Struct Mol Biol, 11 (5): 412-9.
  • Hassett, C., Richter, R. J., Humbert, R., Chapline, C., Crabb, J. W., Omiecinski, C. J., Furlong, C. E. 1991. "Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence." Biochemistry, 30: 10141-9.
  • Hayashi, H., Gotoh, N., Ueda, Y., Nakanishi, H., Yoshimura, N. 2008. “Lysyl oxidase-like 1 polymorphisms and exfoliation syndrome in the Japanese population”, American Journal of Ophthalmology, 145, 582-585.
  • Hoeschen, R. J. 1997. "Oxidative stress and cardiovascular disease.", Can J Cardiol, 13(11):1021-5.
  • Humbert, R., Adler, D. A., Disteche, C. M., Hassett, C., Omiecinski, C. J., Furlong, C. E. 1993. "The molecular basis of the human serum paraoxonase activity polymorphism." Nat Genet, 3: 73-6.
  • Inagaki Y, Mashima Y, Funayama T, Ohtake Y, Fuse N, Yasuda N, Fukuchi T, Murakami A, Hotta Y. 2006. “Paraoxonase 1 gene polymorphisms influence clinical features of open-angleglaucoma”. Graefes Arch Clin Exp Ophthalmol. 244(8):984-90.
  • İrkeç, M. 1979. “Senil psödoeksfoliasyonunun epidemiyolojik özellikleri üzerine bir inceleme”. T Oft Gaz, 263. İskeleli, G. 1978. "Psödoeksfoliasyon sıklığı", XII. Ulusal Oftalmoloji Kongresi, Antalya, 171.
  • Jacobi, P. C., Dietlein, T. S., Krieglstein, G. K. 1999. “Comparative study of trabecular aspiration vs trabeculectomy in glaucoma triple procedure to treat pseudoexfoliation glaucoma”, Archives of Ophthalmology, 117:10, 1311-8.
  • James, R. W., Leviev, I., Righetti, A. 2000b. "Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease.", Circulation, 101: 2252–57.
  • James, R. W., Leviev, I., Ruiz, J., Passa, P., Froguel, P., Garin, M. C. 2000a. "Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients.", Diabetes, 49(8): 1390-3.
  • Jarvik, G. P., Rozek, L. S., Brophy, V. H., Hatsukami, T. S., Richter, R. J., Schellenberg, G. D., Furlong, C. E. 2000. "Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype.", Arterioscler Thromb Vasc Biol, 20: 2441–2447.
  • Kaneto, H., Katakami, N., Kawamori, D. et al. 2007. "Involvement of oxidative stress in the pathogenesis of diabetes.", Antioxid Redox Signal, 9(3):355-66.
  • Kasım, B., İrkeç, M., Alikaşifoğlu, M., Orhan, M., Mocan, M. C., Aktaş, D. 2013. “Association of LOXL1 gene polymorphisms with exfoliation syndrome/glaucoma and primary open angle glaucoma in a Turkish population”, Molecular Vision, 19, 114-20.
  • King, A., Azuara-Blanco, A., Tuulonen, A. 2013. “Glaucoma”, British Medical Journal, 346, f3518.
  • Koliakos, G. G., Befani, C. D., Mikropoulos, D., Ziakas, N. G., Konstas, A. G. 2008. "Prooxidant-antioxidant balance, peroxide and catalase activity in the aqueous humour and serum of patients with exfoliation syndrome or exfoliative glaucoma.", Graefes Arch Clin Exp Ophthalmol, 246(10):1477-83.
  • Koliakos, G. G., Konstas, A. G. P., Schlotzer-Schrehardt, U., Bufidis, T., Georgiadis, N., Ringvold, A. 2002. “Ascorbic acid concentration is reduced in the aqueous humor of patients with exfoliation syndrome” American Journal of Ophthalmology, 134, 879–883.
  • Kuchle, M., Amberg, A., Martus, P., Nguyen, N., Naumann, G.1997. “Pseudoexfoliation syndrome and secondary cataract”, British Journal of Ophthalmology, Oct; 81(10), 862–866.
  • La Du, B. N. 2003. "Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease.", Arterioscler Thromb Vasc Biol, 23: 1317.
  • Lahiri, D. K., Schnabel, B. 1993. "DNA isolation by a rapid method from human blood samples: effects of MgCl 2 , EDTA, storage time, and temperature on DNA yield and quality.", Biochem Genet, 31(7-8): 321-8.
  • Li, W. F., Costa, L. G., Richter, R. J. et al. 2000. "Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates.", Pharmacogenetics, 10: 767-79.
  • Mackness, B., Durrington, P. N., Mackness, M. I. 1998a. "Human serum paraoxonase.", Gen Pharmacol, 31: 329– 336.
  • Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., Durrington, P. N. 1998b, "Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification.", FEBS Lett, 423: 57–60.
  • Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., Julier, K., Abuasha, B., Miller, J. E., Boulton, A. J., Durrington, P. N. 1998c. "Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus.", Atherosclerosis, 139: 341–49.
  • Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., Durrington, P. N. 1997a. "Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon.", Br J Pharmacol, 112: 265– 268.
  • Mackness, M. I., Arrol, S., Mackness, B., Durrington, P. N. 1997b. "The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation.", Lancet, 349:851-2.
  • Mackness, M. I., Arrol, S., Abbott, C. A., Durrington, P. N. 1993. "Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.", Atherosclerosis, 104: 129-35.
  • McElveen, J., Mackness, M. I., Colley, C. M., Peard, T., Warner, S., Walker, C. H. 1986. "Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction.", Clin Chem, 32:671-3.
  • Mitchell, P., Wang, J. J., Hourihan, F. 1999. “The relationship between glaucoma and pseudoexfoliation: the Blue Mountains Eye Study”, Archives of Ophthalmology, 117, 1319-24.
  • Mitchell, P., Wang, J. J., Smith, W. 1997. "Association of pseudoexfoliative syndrome with increased vascular risk.", Am J Ophtalmol, 124:684-7.
  • Naumann, G. O., Schlötzer-Schrehardt, U., Küchle, M. 1998. “Pseudoexfoliation syndrome for the comprehensive ophthalmologist. Intraocular and systemic manifestations”, Ophthalmology, 105(6), 951-68.
  • Ozaki, M., Lee, K. Y., Vithana, E. N., Yong, V. H., Thalamuthu, A., Mizoguchi, T., Venkatraman, A., Aung, T. 2008. “Association of LOXL1 gene polymorphisms with pseudoexfoliation in the Japanese”, Investigative Ophthalmology and Visual Science, 49(9), 3976-80.
  • Örgen, L. 1949. “Kapsüler eksfoliasyon”, Oto Nöro Oftalmoloji, 4,1.
  • Pasutto, F., Krumbiegel, M., Mardin, C. Y., Paoli, D., Lämmer, R., Weber, B. H., Kruse, F. E., Schlötzer-Schrehardt, U., Reis, A. 2008. “Association of LOXL1 Common Sequence Variants in German and Italian Patients with Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma”, Investigative Ophthalmology and Visual Science, 49,1459-63.
  • Playfer, J. R., Eze, L. C., Bullen, M. F., Evans, D. A. 1976. "Genetic polymorphism and interethnic variability of plasma paroxonase activity.", J Med Genet, 13: 337–342.
  • Ramprasad, V. L., George, R., Soumittra, N., Sharmila, F., Vijaya, L., Kumaramanickavel, G. 2008. “Association of nonsynonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India”, Molecular Vision, 14, 318- 322.
  • Resnikoff, S., Pascolini, D., Etya’ale, D, Kocur, I., Pararajasegaram, R., Pokharel, G. P., Mariotti, S. P. 2004. “Global data on visual impairment in the year 2002”, Bulletin of the World Health Organization, 82 (11), p. 844–851.
  • Richardson, T. M., Epstein, D. L. 1981. “Exfoliation glaucoma: a quantitative perfusion and ultrastructural study”, Ophthalmology, 88(9), 968–980.
  • Ringvold, A. 1999. “Epidemiology of the pseudo-exfoliation syndrome”, Acta Ophthalmologica Scandinavica, 77, 371–375.
  • Ritch, R., Schlotzer-Schrehardt, U. 2001. “Exfoliation syndrome”, Survey of Ophthalmology, 45(4), 265-315. Samarai, V., Samarei, R., Haghighi, N., Jalili, E. 2012. “Sensory-neural hearing loss in pseudoexfoliation syndrome”, International Journal of Ophthalmology, 5(3), 393-396.
  • Schmidt, H., Schmidt, R., Niederkorn, K. 1998. “Paraoxonase PON1 polymorphism Leu–Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study”, Stroke, 29:2043–8.
  • Schmidt, R., Schmidt, H., Fazekas, F. 2000. “MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: three-year follow-up of the Austrian Stroke Prevention Study”, Arterioscler Thromb Vascular Biology, 20:1811–6.
  • Schlotzer-Schrehardt, U., Kuchle, M., Naumann, G.O. 1991. “Electron-microscopic identification of pseudoexfoliation material in extrabulbar tissue”, Archives of Ophthalmology, 109(4), 565–570.
  • Schlötzer-Schrehardt, U. 2012. “Pseudoexfoliation syndrome: the puzzle continues”, Journal of Ophthalmic and Vision Research, 7, 187-189.
  • Schlötzer-Schrehardt, U., Koca, M., Naumann, G. O. H., Volkholz, H. 1992. “Pseudoexfoliation syndrome: ocular manifestation of a systemic disorder?”, Archives of Ophthalmology, 110, 1752–6.
  • Schlötzer-Schrehardt, U., Küchle, M., Jünemann, A., Naumann, G. O. 2002. “Relevance of the pseudoexfoliation syndrome for the glaucomas”, Ophthalmologe, 99, 683-90.
  • Schlötzer-Schrehardt, U., Naumann, G. O. 2006. “Ocular and systemic pseudoexfoliation syndrome”, American Journal of Ophthalmology, 141, 921-937.
  • Sein, J., Galor, A., Sheth, A., Kruh, J., Pasquale, L. R., Karp, C. L. 2013. “Exfoliation syndrome: new genetic and pathophysiologic insights”, Current Opinion in Ophthalmology, 24(2), 167-74.
  • Seneş, M., Kazan, N., Coşkun, O., Zengi, O., Inan, L., Yücel, D. 2007. "Oxidative and nitrosative stress in acute ischaemic stroke.", Ann Clin Biochem, 44(Pt 1):43-7.
  • Shih, D. M., Gu, L., Hama, S., Xia, Y-R., Navab, M., Fogelman, A. M., Lusis, A. J. 1996. "Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model.", J Clin Invest, 97: 1630–1639.
  • Sorenson, R. C., Bisgaier, C. L., Aviram, M., Hsu, C , Billecke, S., La Du, B. N. 1999. "Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity.", Arterioscler Thromb Vasc Biol, 19: 2214-25.
  • Spector, A. 1995. "Oxidative stress-induced cataract: mechanisms of action.", FASEB J, 9:1173-82.
  • Streeten, B. W., Gibson, S. A., Dark, A. J. 1986. “Pseudoexfoliative material contains an elastic microfibrillarassociated glycoprotein”, Transactions of the American Ophthalmological Society, 84, 304–320.
  • Streeten, B. W., Li, Z. Y., Wallace, R. N., Eagle, R. C., Keshgegian, A. A. 1992. “Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome”, Arch Ophthalmology, 110, 1757–1762.
  • Suehiro, T., Nakamura, T., Inoue, M., Shiinoki, T., Ikeda, Y., Kumon, Y., Shindo, M., Tanaka, H., Hashimoto, K. 2000. "A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression.", Atherosclerosis, 150: 295-298.
  • The Eye Diseases Prevalence Research Group, 2004. “Causes and prevalence of visual impairment among adults in the United States”. Archives of Ophthalmology, 122, 477-485.
  • Thorleifsson, G., Magnusson, K. P., Sulem, P., Walters, G. B., Gudbjartsson, D. F., Stefansson, H., Jonsson, T., Jonasdottir, A., Jonasdottir, A., Stefansdottir, G., Masson, G., Hardarson, G. A., Petursson, H., Arnarsson, A., Motallebipour, M., Wallerman, O., Wadelius, C., Gulcher, J. R., Thorsteinsdottir, U., Kong, A., Jonasson, F., Stefansson, K. 2007. “Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma”, Science, 317, 1397-1400.
  • Tomás, M., Sentí, M., Elosua, R., et al. 2001. “Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity,” European Journal of Pharmacology, vol. 432, no. 2-3, pp. 121–128.
  • Tougou, K., Nakamura, A., Watanabe, S., Okuyama, Y., Morino, A. 1998. "Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent.", Drug Metab Dispos, 26(4): 355-9.
  • Williams, S. E., Whigham, B. T., Liu, Y., Carmichael, T. R., Qin, X., Schmidt, S.,Ramsay, M., Hauser, M. A., Allingham, R.R., 2010. “Major LOXL1 risk allele is reversed in exfoliation glaucoma in a black South African population”, Molecular Vision,16, 705-12.
  • Yalaz, M., Othman, I., Nas, K., Eroglu, A., Homurlu, D., Çıkıntaş, Z., Ashouri, A. 1992. “The frequency of pseudoexfoliation syndrome in the eastern Mediterranean area of Turkey”, Acta Ophthalmology (Copenhagen), 70, 209-213.
  • Yalvaç, I., Önal, M. 2001. Temel Göz Hastalıkları, 259-285. Glokom (1. Baskı). Editörler: Aydın, P., Akova, Y. A. Ankara: Güneş Kitabevi.
  • Yang, X., Zabriskie, N. A., Hau, V. S., Chen, H., Tong, Z., Gibbs, D., Farhi, P., Katz, B. J., Luo, L., Pearson, E., Goldsmith, J., Ma, X., Kaminoh, Y., Chen, Y., Yu, B., Zeng, J., Zhang, K.,Yang, Z. 2008. “Genetic association of LOXL1 gene variants and exfoliation glaucoma in a Utah cohort”, Cell Cycle, 7(4), 521-4.
  • Yilmaz, A., Adiguzel, U., Tamer, L., Yildirim, O., Oz, O., Vatansever, H., Ercan, B., Değirmenci, U. S., Atik, U. 2005. “Serum oxidant/antioxidant balance in exfoliation syndrome”, Clinical and Experimental Ophthalmology, 33, 63–66.
  • Zech, R., Zurcher, K. 1974 "Organophosphate splitting serum enzymes in different mammals.", Comp Biochem Physiol, 48: 427–433.
  • Zhou, L., Zhao, S. Z., Koh, S. K., Chen, L., Vaz, C., Tanavde, V., Li, X. R., Beuerman, R. W. 2012. “In-depth analysis of the human tear proteome”, Journal of Proteomics, 75(13), 3877-85.
  • Zhou G, Liu B. 2010. “Single nucleotide polymorphisms of metabolic syndrome-related genes in primary open angle glaucoma”.Int J Ophthalmol 3(1):36-42.
APA DEMİRDÖĞEN B, MUMCUOĞLU T, ÖZGE G (2017). Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. , 1 - 54.
Chicago DEMİRDÖĞEN Birsen Can,MUMCUOĞLU Tarkan,ÖZGE Gökhan Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. (2017): 1 - 54.
MLA DEMİRDÖĞEN Birsen Can,MUMCUOĞLU Tarkan,ÖZGE Gökhan Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. , 2017, ss.1 - 54.
AMA DEMİRDÖĞEN B,MUMCUOĞLU T,ÖZGE G Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. . 2017; 1 - 54.
Vancouver DEMİRDÖĞEN B,MUMCUOĞLU T,ÖZGE G Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. . 2017; 1 - 54.
IEEE DEMİRDÖĞEN B,MUMCUOĞLU T,ÖZGE G "Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması." , ss.1 - 54, 2017.
ISNAD DEMİRDÖĞEN, Birsen Can vd. "Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması". (2017), 1-54.
APA DEMİRDÖĞEN B, MUMCUOĞLU T, ÖZGE G (2017). Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. , 1 - 54.
Chicago DEMİRDÖĞEN Birsen Can,MUMCUOĞLU Tarkan,ÖZGE Gökhan Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. (2017): 1 - 54.
MLA DEMİRDÖĞEN Birsen Can,MUMCUOĞLU Tarkan,ÖZGE Gökhan Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. , 2017, ss.1 - 54.
AMA DEMİRDÖĞEN B,MUMCUOĞLU T,ÖZGE G Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. . 2017; 1 - 54.
Vancouver DEMİRDÖĞEN B,MUMCUOĞLU T,ÖZGE G Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması. . 2017; 1 - 54.
IEEE DEMİRDÖĞEN B,MUMCUOĞLU T,ÖZGE G "Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması." , ss.1 - 54, 2017.
ISNAD DEMİRDÖĞEN, Birsen Can vd. "Paraoksonaz 1 (PON1) Genetik Polimorfizmlerinin Psödoeksfoliasyon Sendromu ve Psödoeksfoliasyon Glokomu’ndaki Rolünün Araştırılması". (2017), 1-54.